Creative Biolabs provides an ADCC evaluation service for antibody functional activity that employs advanced cell-based assays and fragment crystallizable region (Fc) engineering insights to comprehensively assess and optimize the cytotoxic potential of therapeutic antibody candidates, thereby streamlining drug development and supporting the characterization of immune effector mechanisms.
Antibody-dependent cellular cytotoxicity (ADCC) is a crucial immune effector mechanism by which therapeutic antibodies eliminate target cells, primarily through the recruitment of natural killer (NK) cells. It represents a cornerstone of modern antibody-based therapies for various diseases, including cancer.
Creative Biolabs offers precise and comprehensive ADCC evaluation, directly addressing critical challenges in therapeutic antibody development. We help you confidently select and optimize lead candidates by providing robust data on their ability to mediate target cell destruction. Our service delivers quantifiable outcomes, enabling you to understand the full immune-modulating potential of your antibodies.
Our technical services are designed to rigorously assess how your antibody candidates trigger immune responses at the cellular level. Utilizing diverse cell models, we facilitate in-depth studies of immune signaling pathways and critical immune cell interactions. This detailed analysis assists clients in simulating complex immune microenvironments, enabling precise drug screening and lead optimization.
Discover how we can help - Request a consultation.
Explore our ADCC evaluation services - Get a quote today.
Summary: The pH-selective interaction between an antibody's crystallizable region and the neonatal receptor is key for prolonging antibody circulation via intracellular trafficking and recycling. Directed evolution identified mutations improving pH-dependent receptor binding and serum persistence of model antibodies and fusion proteins. They boosted cancer cell-clearing cytotoxic activities, which can be silenced while retaining good pH-dependent binding, promising to enhance therapeutic antibodies' pharmacokinetics and potency.
Fig.1 ADCC and CDC activity evaluation in antibody pharmaceuticals.1
By providing robust and reliable data on your antibody's functional activity early in the development process, ADCC evaluation allows for more informed decision-making. This accelerates lead candidate selection, de-risks preclinical development, and can prevent costly failures in later stages by identifying the most potent molecules sooner.
Absolutely. Our expertise extends to custom assay development. If your antibody targets a novel or rare antigen, our scientific team can work with you to design and validate a bespoke ADCC assay using appropriate target cell models and effector cells, ensuring accurate and meaningful functional assessment.
Our services leverage extensive experience, state-of-the-art equipment, and rigorous quality control standards, minimizing variability and ensuring high reproducibility. We utilize well-qualified primary human effector cells and expertly maintained engineered cell lines, leading to more robust and physiologically relevant data.
Creative Biolabs stands as a leader in ADCC evaluation due to our unparalleled scientific expertise, cutting-edge technology, and commitment to client success. We integrate a deep understanding of immunology and antibody engineering to deliver highly accurate, reproducible, and physiologically relevant data.
Ready to advance your therapeutic antibody program with precise ADCC evaluation and comprehensive quality characterization? Reach out to our expert team today.
Reference
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
